Differences

This shows you the differences between two versions of the page.

--- research:concordance_with_aad_guidelines_for_the_treatment_of_acne_vulgaris [2016/10/18 17:48]
schillil
+++ research:concordance_with_aad_guidelines_for_the_treatment_of_acne_vulgaris [2020/04/29 21:09] (current)
crundle
@@ Line 1: / Line 1: @@
-====== Oral tetracycline-class Antibiotic Use for Acne Therapy ======
+=====Characterization of Oral Antibiotics for Acne Treatment======
-**Objective:** //The objective of this study is to 1) characterize the use of tetracycline-class antibiotics for the treatment of acne in children and adolescents and 2) expand upon a recent study to more fully describe acne oral tetracycline-class antibiotic use around the world //
+**Objective:**
+Aim 1: Characterize the international distribution of oral antibiotic use for acne in the pediatric and young adult population ages 12 to 20.
+Aim 2: Characterize the international distribution of oral antibiotic use for acne in the adult population ages 21 to 40.
-**Rationale:** //Acne is a common and disabling medical problem, especially among adolescents. The American Academy of Dermatology (AAD) has published guidelines for the use of systemic antibiotics for the management of acne. These include: 1) minimizing the duration of therapy (ideally to 3-4 months and no longer than 6 months) to decrease risk of resistance and 2) prescribing concomitant treatment with a topical retinoid or topical retinoid/benzoyl peroxide to increase efficacy. In addition to promoting resistance, long-term oral antibiotic use has been associated with a number of adverse events including microbiome disruption and pharyngitis, and potentially inflammatory bowel disease and obesity. Yet oral antibiotics are often over-prescribed. A large retrospective cohort study of teenagers in the UK revealed that of antibiotic courses prescribed by general practitioners, 29% exceeded 6 months in duration, and 62% were not associated with a topical retinoid. Our study aims to describe the type and duration of oral tetracycline-class antibiotic therapy for the treatment of acne around the world. The evidence through the OHDSI network may help identify a need to improve concordance to achieve the best treatment efficacy for patients.//
+//**Rationale:** //
+Acne is a common and disabling medical condition, particularly amongst adolescents and young adults.[1]  According to the Global Burden of Disease Study 2016, acne is the most disabling skin condition worldwide, responsible for 0.28% of global burden from all diseases.[2]  In addition to physical disfigurement, the profound psychosocial effects of acne have been recognized for over half a century.[3]  Guidelines established by the American Academy of Dermatology recommend minimizing the duration of systemic antibiotics for the management of acne ideally to 3-4 months and no longer than 6 months in order to decrease risk of resistance.[1]  A recent systematic review demonstrated that over 50% of P. acnes strains are reported as resistant in all major regions of the world.[4]  In addition to promoting resistance, long-term oral antibiotic use has been associated with a number of adverse events including microbiome disruption and pharyngitis, as well as possible associations with inflammatory bowel disease and obesity.[5]  Despite these adverse effects, oral antibiotics are often prescribed for acne for longer durations than acne guidelines recommend.[5]  A large retrospective cohort study of teenagers in the UK revealed that 29% of antibiotic courses prescribed by general practitioners exceeded 6 months in duration.[5]  A similar retrospective cohort study of teenagers and young adults in the US found that 18% of antibiotic courses exceeded 6 months.[6]  Our study will investigate oral antibiotic use for acne over the last ten years across the globe in both pediatric/young adult and adult populations.  OHDSI network evidence will identify areas of the globe most in need of improving guideline concordance//.//
-**Project Lead(s):** //Stephanie Chapman, Renee Domozych, Jessica Mounessa, Jonathan Silverberg, David Barbieri, David Margolis, Robert P. Dellavalle, Lisa Schilling//
+**Project Lead(s):**  //Robert P. Dellavalle, Lisa M. Schilling//
-**Full protocol:** {{:research:acne_vulgaris_full_study_protocol.docx|Acne vulgaris treatment study protocol}}
+**Coordinating Institution(s):** //University of Colorado School of Medicine//
-Please provide any comments or suggestions.
-===== Forum Discussion Thread =====
+**Additional Participants:** // //Chante Karimkhani: ck2525@caa.columbia.edu
-[[http://forums.ohdsi.org/t/ohdsi-study-concordance-with-antibiotic-treatment-guidelines-for-acne/1703]]//
+Chandler Rundle: chandler.rundle@gmail.com
+Megan Branda: MEGAN.BRANDA@cuanschutz.edu
+John Barbieri: john.barbieri@uphs.upenn.edu
+Chris Knoll: cknoll1@its.jnj.com
+David Margolis: margo@mail.med.upenn.edu
+Patrick Ryan: ryan@ohdsi.org
+Martijn Schuemie: m.schuemie@erasmusmc.nl
+Jonathan Silverberg: JonathanISilverberg@gmail.com
+Dylan Ray: DYLAN.RAY@cuanschutz.edu
+Sara Deakyne: Sara.DeakyneDavies@childrenscolorado.org
+**Full Draft Protocol:** //Please provide any comments or suggestions.//
+[[https://docs.google.com/document/d/1LnugUQrloOn-3cZJDdTpgVYEsynu7SBztFtjzjAuEDE/edit]]
+**Initial Proposal Date:** //25 August 2016//
+**Launch Date:** //  //
+**Study Closure Date:** // //
+**Forum Discussion Thread**
+http://forums.ohdsi.org/t/ohdsi-study-concordance-with-antibiotic-treatment-guidelines-for-acne/1703

Observational Health Data Sciences and Informatics

User Tools

Site Tools

Differences

Page Tools